US FDA’s Center for Drug Evaluation & Research Director Janet Woodcock, MD, will spend at least the next six months as acting head of the Office of New Drugs to implement policy and structural changes to the review process for new drugs and biologics.
CDER Director Woodcock Plans Changes To Drug Reviews During OND Transition
In podcast interview, US FDA’s Center for Drug Evaluation & Research Director Janet Woodcock discusses her plans the Office of New Drugs, including changes to the structure of the office to make reviews better managed and more uniform across divisions. Woodcock says she expects to stay in the interim OND role for most of 2017.
